Re-evaluating Antibiotic Use in End-of-Life Care: Benefits vs. Burdens

The European Medical Journal (EMJ) has recently published an article that critically examines the practice of antibiotic use at the end of life, questioning its widespread application due to often limited symptom relief and significant associated treatment burdens. This timely discussion highlights a persistent clinical and ethical tension within palliative care: balancing the potential benefits of antimicrobials with their practical and societal drawbacks. One of the primary claims underscored by the EMJ article, and corroborated by extensive medical literature, is the inconsistent and often unpredictable nature of symptom relief provided by antibiotics in terminally ill patients. While antibiotics are frequently administered with the intention of alleviating discomfort caused by infections, evidence suggests that their effectiveness varies greatly depending on the type of infection. For instance, some studies indicate that symptomatic improvement is more likely for urinary tract infections (60-92% response rate) compared to respiratory infections (0-53% response rate), and general symptom relief is observed in a relatively modest percentage of cases (ranging from 37% to 56.7%). For conditions like sepsis, about half of patients might experience improvement, but overall, antibiotics have not consistently shown significant improvement in symptoms beyond specific types of infections like urinary tract infections. Furthermore, when a patient's prognosis is in the range of days to weeks, antibiotics have often not demonstrated a significant survival benefit. Beyond the variable efficacy, a major point of concern is the substantial burden that antibiotic treatment can impose on patients nearing the end of life. These burdens are multifaceted and can include adverse drug reactions such as diarrhea, nausea, allergic reactions, and the risk of *Clostridioides difficile* infection. The administration of intravenous antibiotics often necessitates venous access, which can cause discomfort and distress for frail patients. Additionally, the diagnostic procedures required to identify infections (e.g., blood draws, chest X-rays, bladder catheterization) can be invasive and add to the patient's discomfort and overall burden. In some cases, antibiotic treatment may even lead to hospital transfers, detracting from a patient's wish to remain in a home or hospice setting for comfort care. The financial cost of antibiotic therapy also presents a practical burden to healthcare systems and potentially families. The ethical considerations surrounding antibiotic use at the end of life are profound and form a core part of the discussion. Clinicians and families often face the dilemma of whether to treat an infection, with concerns that such interventions might unintentionally prolong the dying process without improving quality of life, or even create false hope for recovery. There is a delicate balance between the ethical principles of beneficence (doing good for the patient) and non-maleficence (avoiding harm). The principle of respect for patient autonomy dictates that decisions should align with the patient's values and goals of care. However, adequately informing patients and surrogates about the limited benefits and potential harms of antibiotics can be challenging. Many patients and their families, or even healthcare professionals, may be reluctant to withhold antibiotics, driven by a perception that not treating an infection will shorten life or by an inherent desire to fight illness. Another critical concern highlighted in the discourse is the contribution of antibiotic overuse to the global problem of antimicrobial resistance (AMR). The widespread and sometimes inappropriate use of antibiotics, even in end-of-life care where benefits may be minimal, can accelerate the development of drug-resistant pathogens, posing a significant public health threat. This societal harm needs to be weighed against individual patient benefits, especially when the latter are uncertain. The lack of clear, evidence-based guidelines for antibiotic use in patients at the end of life is a significant challenge for healthcare providers. This absence of standardized protocols leads to variability in prescribing practices and can make decision-making difficult for clinicians. Several sources call for more research, particularly prospective studies, to generate better evidence to guide appropriate prescription practices in palliative care. Given these complexities, the article and corroborating sources strongly advocate for shared decision-making and robust antibiotic stewardship programs in end-of-life care. Shared decision-making involves open and honest conversations between clinicians, patients, and their families about the patient's goals of care, prognosis, the specific type of infection, and the realistic benefits and burdens of antibiotic therapy. This approach ensures that treatment choices align with the patient's values, particularly when the priority shifts towards comfort rather than life prolongation. Antibiotic stewardship, which focuses on optimizing antibiotic use, is crucial in this context to minimize harms, reduce resistance, and ensure that antibiotics are prescribed only when there is a clear benefit to the individual. Incorporating non-antibiotic symptom management strategies should also be a key part of the care plan when infection is suspected. This discussion is globally relevant, including for audiences in India, where palliative care services are expanding, and ethical considerations in end-of-life care are gaining increasing attention. The principles of balancing patient comfort, minimizing burden, and addressing antimicrobial resistance are universal healthcare challenges. The EMJ article serves as a crucial reminder for healthcare professionals worldwide to critically re-evaluate antibiotic use in the context of terminal illness, promoting thoughtful, patient-centered care over routine administration.

Frequently Asked Questions

Read Full Story on Quick Digest